Biocon Biologics’ commercial footprint for biosimilars straddles advanced and emerging market countries and stretches to over 100 countries. Biocon Biologics’ products are marketed globally through a hybrid commercial model, wherein the company has direct commercial presence in a few countries and in others, the company leverages the commercial strengths of its partners.

In emerging markets, Biocon Biologics makes its biosimilars available to patients through partnerships with leading local pharmaceutical players. This organically developed B2B business has increased its breadth by entering new countries through regional partnerships and addition of new products following approval in developed markets.